Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Quanterix ( (QTRX) ).
Quanterix Corporation has entered into a merger agreement to acquire Akoya Biosciences in an all-stock transaction, creating an integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers. This merger is expected to enhance Quanterix’s market position by expanding its technology offerings in high-growth areas such as neurology, oncology, and immunology, and is projected to generate significant annual cost synergies, with positive free cash flow anticipated by 2026.
More about Quanterix
Quanterix Corporation is a company specializing in ultra-sensitive biomarker detection, driving scientific discovery with its Simoa® technology. It offers precision instruments and digital immunoassay technology for research and diagnostics in fields like neurology, oncology, immunology, cardiology, and infectious diseases. Akoya Biosciences, known as The Spatial Biology Company®, provides single-cell imaging solutions to enhance understanding of disease progression and response to therapy. The company focuses on spatial phenotyping to serve researchers across various research stages.
YTD Price Performance: 9.01%
Average Trading Volume: 398,247
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $451.9M
For detailed information about QTRX stock, go to TipRanks’ Stock Analysis page.
